Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor
Public ClinicalTrials.gov record NCT00848172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Double-Blind, Placebo Controlled Pilot-Study of Octanoic Acid in Essential Tremor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Background: * Essential tremor (ET) is a neurological disorder characterized by uncontrollable shaking. Several medications are used to treat ET; however, they are often only partly effective and can have side effects. * Research studies have shown that octanol, a food additive similar to alcohol, can improve tremor in animals. Octanol is less likely to make people drunk than alcohol. Two earlier NIH studies found that one form of octanol, called 1-octanol, did improve tremor in some people and had few side effects. * In the body, 1-octanol is converted to octanoic acid. Researchers are interested in finding out whether octanoic acid can help people with ET. Objectives: * To find out if octanoic acid can improve hand tremor in people with essential tremor. * To measure levels of octanoic acid in the blood after it is taken. Eligibility: * Patients 21 years of age and older with ET, who are willing to abstain from alcohol, caffeine, and all medications as required by the study and who are willing and able to fast for up to 12 hours at a time. * Participants may not be of Asian or Native American ancestry because of genetic susceptibilities to the intoxicating effects of the study drug. Design: * This study requires a 3-day hospital admission as well as two outpatient visits. * Visit 1 (outpatient): Screening visit and blood alcohol level test * Medical history, physical and neurological examination, a blood test, and an electrocardiogram to measure heart function. Women who are able to get pregnant will have a urine pregnancy test. * Patients will consume 1.5 ounces of alcohol per drink (up to three drinks at least 30 minutes apart), and be tested to evaluate how the tremor responds. Researchers will draw blood to measure blood alcohol level about 1 hour after the first drink and closely monitor patients for signs of intoxication. * Inpatient examination * Preparation: Researchers will prepare a schedule to stop any tremor medications that patients might be on. Patients may not drink alcohol or eat or drink anything with caffeine, including chocolate, for at least 2 days before admission. * Day 1: Vital signs, blood (and urine pregnancy) tests, and electrocardiogram. Patients will be asked to wear a tremor monitor, similar to a wristwatch. Patients will also have IV lines inserted for blood draws. * Days 2 and 3: Randomized study medication (octanoic acid on one day, placebo on the other day). Patients will fast before taking the drug, but will be allowed to eat and drink after the tests are completed (around noon). * Blood will be drawn before taking the study drug and again (a total of nine times) after taking the drug. * Tremor will be measured during the study, before and after taking the drug. * Visit 2 (outpatient): 4 to 7 days after discharge * Blood test and an electrocardiogram, and a series of questionnaires regarding the study.
Study identification
- NCT ID
- NCT00848172
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 29 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2009
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Dec 26, 2012
2009 – 2010
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Essential Tremor trials
Other public records listing Essential Tremor. Sorted by last update posted; newest first. Not a recommendation.
- NCT07721272: Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation Not yet recruiting
- NCT06087276: Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) Active, not recruiting
- NCT07599592: Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor Recruiting
- NCT05897775: Coordinated Reset Deep Brain Stimulation for Essential Tremor Recruiting
- NCT06293638: Functional Brain Network Changes in Patients Undergoing Deep Brain Stimulation for Essential Tremor Recruiting
- NCT03664609: Deep Brain Stimulation (DBS) Retrospective Outcomes Study Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00848172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 26, 2012 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00848172 live on ClinicalTrials.gov.